Abstract
Gene delivery in cystic fibrosis is hampered by extracellular and intracellular biological barriers and inefficient vectors. Although progress is evident, continued bioengineering of DNA, vectors, and delivery technologies will be critical to ensure biocompatibility, safety, and therapeutic effectiveness. Both viral and nonviral vectors demonstrate insufficient gene expression to adequately correct chloride ion and respiratory homeostasis, but vector modifications and novel vector types continue to advance understanding of transfection processes, immunobiological responses, and cystic fibrosis pathology. Interactions of toll-like receptors and other coreceptors may be critical components of cystic fibrosis immunobiology but additional research will be needed before causative associations are widely established; however, receptor modulation provides a theoretical framework to develop new therapeutic approaches. Clinical-phase pharmacotherapies offer short-term promise to restore electrolyte imbalance and/or symptomatology, but it may be many years before gene therapy offers a curative solution for the disease.
Keywords: Cystic fibrosis, gene therapy, viral vectors, nonviral vectors, transfection, toll-like receptors, progress
Current Gene Therapy
Title: Cystic Fibrosis, Vector-Mediated Gene Therapy, and Relevance of Toll-Like Receptors: A Review of Problems, Progress, and Possibilities
Volume: 8 Issue: 3
Author(s): Timothy J. Atkinson
Affiliation:
Keywords: Cystic fibrosis, gene therapy, viral vectors, nonviral vectors, transfection, toll-like receptors, progress
Abstract: Gene delivery in cystic fibrosis is hampered by extracellular and intracellular biological barriers and inefficient vectors. Although progress is evident, continued bioengineering of DNA, vectors, and delivery technologies will be critical to ensure biocompatibility, safety, and therapeutic effectiveness. Both viral and nonviral vectors demonstrate insufficient gene expression to adequately correct chloride ion and respiratory homeostasis, but vector modifications and novel vector types continue to advance understanding of transfection processes, immunobiological responses, and cystic fibrosis pathology. Interactions of toll-like receptors and other coreceptors may be critical components of cystic fibrosis immunobiology but additional research will be needed before causative associations are widely established; however, receptor modulation provides a theoretical framework to develop new therapeutic approaches. Clinical-phase pharmacotherapies offer short-term promise to restore electrolyte imbalance and/or symptomatology, but it may be many years before gene therapy offers a curative solution for the disease.
Export Options
About this article
Cite this article as:
Atkinson J. Timothy, Cystic Fibrosis, Vector-Mediated Gene Therapy, and Relevance of Toll-Like Receptors: A Review of Problems, Progress, and Possibilities, Current Gene Therapy 2008; 8 (3) . https://dx.doi.org/10.2174/156652308784746468
DOI https://dx.doi.org/10.2174/156652308784746468 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases
Current Medicinal Chemistry Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC.
Reviews on Recent Clinical Trials Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer
Current Topics in Medicinal Chemistry Evaluation of Cytotoxic Mechanisms of Clinacanthus Nutans Extracts in Cancer Cells
The Natural Products Journal A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
Current Cancer Drug Targets Lung Cancer Brachytherapy
Current Cancer Therapy Reviews Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery Synthetic Methods of Quinoline Derivatives as Potent Anticancer Agents
Mini-Reviews in Medicinal Chemistry The Efficacy of Vitamin K, A Member Of Naphthoquinones in the Treatment of Cancer: A Systematic Review and Meta-Analysis
Current Cancer Drug Targets Rapid Characterization of a Novel Taspine Derivative-HMQ1611 Binding to EGFR by a Cell Membrane Chromatography Method
Combinatorial Chemistry & High Throughput Screening Garlic-Derived Allyl Sulfides in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Polysulfated/Sulfonated Compounds for the Development of Drugs at the Crossroad of Viral Infection and Oncogenesis
Current Pharmaceutical Design N-Hydroxyguanidines as Substrates of Nitric Oxide Synthases
Current Topics in Medicinal Chemistry Sugar Based Biopolymers in Nanomedicine; New Emerging Era for Cancer Imaging and Therapy
Current Topics in Medicinal Chemistry Some Thiazole Derivatives Combined with Different Heterocycles: Cytotoxicity Evaluation and Apoptosis Inducing Studies
Anti-Cancer Agents in Medicinal Chemistry Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope
Reviews on Recent Clinical Trials Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets CYP4Z1 – A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer
Current Pharmaceutical Design Pharmacogenetics of Childhood Acute Lymphoblastic Leukemia
Current Pharmacogenomics